EP300 and prostate cancer: The p300 inhibitor A485 inhibits acetylation of H3 at the CD274 (encoding PD-L1) promoter site and blocks CD274 transcription, providing a mechanistic basis for the combination of A485 and anti-PD-L1 antibodies in the treatment of prostate cancer [70].Treatment of hepatocellular carcinoma (HCC) with the p300 inhibitor B029-2 inhibits the transcription of six metabolic genes, PSPH, PSAT1, ALDH18A1, ATIC, TALDO1 and DTYMK by blocking the binding of H3K18ac and H3K27Ac to the relevant promoters [71].